Zoe LE van Kempen
Overview
Explore the profile of Zoe LE van Kempen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van Kempen Z, Hogenboom L, Killestein J
Mult Scler
. 2022 Jan;
28(5):693-695.
PMID: 34994665
No abstract available.
12.
van Kempen Z, Toorop A, Sellebjerg F, Giovannoni G, Killestein J
Mult Scler
. 2021 Dec;
28(13):2001-2009.
PMID: 34949134
Over the past two decades, treatment options for patients with multiple sclerosis (MS) have increased exponentially. In the current therapeutic landscape, "no evidence of MS disease activity" is within reach...
13.
Toorop A, Rispens T, Strijbis E, van Oosten B, de Jong B, Uitdehaag B, et al.
Mult Scler
. 2021 Dec;
28(2):323-326.
PMID: 34931887
In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations...
14.
van Kempen Z, Killestein J, Hartung H
Mult Scler
. 2021 Nov;
27(14):2123-2125.
PMID: 34783282
No abstract available.
15.
van Lierop Z, Toorop A, van Ballegoij W, Olde Dubbelink T, Strijbis E, de Jong B, et al.
Mult Scler
. 2021 Jul;
28(7):1121-1125.
PMID: 34240631
In this observational study, 159 patients with multiple sclerosis received personalized dosing of ocrelizumab incentivized by the COVID-19 pandemic. Re-dosing was scheduled when CD19 B-cell count was ⩾10 cells/µL (starting...
16.
Loonstra F, van Kempen Z, Strijbis E, Killestein J, Hoitsma E, Mostert J
Mult Scler
. 2020 Oct;
27(10):1626-1627.
PMID: 33064043
No abstract available.
17.
Loonstra F, Hoitsma E, van Kempen Z, Killestein J, Mostert J
Mult Scler
. 2020 Jul;
26(10):1256-1260.
PMID: 32662742
Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis (MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the Dutch...
18.
Loonstra F, van Rossum J, van Kempen Z, Rispens T, Uitdehaag B, Killestein J
Mult Scler
. 2019 Jun;
26(12):1590-1593.
PMID: 31237826
This retrospective cohort study assessed the timing of infusion-related adverse events (IAEs) during natalizumab (NTZ) administration in well-documented relapsing-remitting multiple sclerosis (RRMS) patients who had received NTZ infusions in our...
19.
van Kempen Z, Rispens T, Killestein J
Mult Scler
. 2017 Oct;
24(6):822-823.
PMID: 28990853
No abstract available.
20.
Leurs C, van Kempen Z, Dekker I, Balk L, Wattjes M, Rispens T, et al.
Mult Scler
. 2017 Aug;
24(11):1453-1460.
PMID: 28823223
Background: Natalizumab is an effective treatment in relapsing-remitting multiple sclerosis (MS). Mainly because of the risk of progressive multifocal leukoencephalopathy (PML), a substantial proportion of John Cunningham (JC) virus-positive patients...